Yes, maintenance therapy after induction without a stem cell transplant (SCT) is absolutely possible. For those who aren't candidates for a transplant, or who choose to delay or skip it, maintenance therapy is still a key part of keeping myeloma under control. Common maintenance therapy options in this situation may Show Full Answer
Yes, maintenance therapy after induction without a stem cell transplant (SCT) is absolutely possible. For those who aren't candidates for a transplant, or who choose to delay or skip it, maintenance therapy is still a key part of keeping myeloma under control. Common maintenance therapy options in this situation may include:
- Lenalidomide (Revlimid) – often the go-to choice, generally well-tolerated
- Bortezomib (Velcade) – particularly for those with high-risk genetic features
- Daratumumab (Darzalex) – a monoclonal antibody sometimes used in maintenance
- Corticosteroids like dexamethasone or prednisone, often combined with other drugs
The goal remains the same — keep myeloma in remission as long as possible while managing side effects. Research suggests that longer maintenance therapy tends to offer greater benefits, with many doctors recommending it continue indefinitely — as long as it's tolerable. It's worth having an open conversation with your oncologist about which option suits your specific situation best.
July 13
Join
Your Privacy Choices
